SDGR · XBRL financial data

Schrodinger financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (SDGR's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	108,095	137,931	180,955	216,666	207,539	255,869
Revenue from contracts with customers	108,095	137,931	180,955	216,666	207,539	255,869
Cost of revenue	44,623	72,311	79,933	75,974	75,456	113,255
Gross profit	63,472	65,620	101,022	140,692	132,083	142,614
Research and development	64,695	90,904	126,372	181,766	201,785	173,138
General and administrative	41,898	64,009	90,825	99,148	99,677	95,409
Total operating expenses	124,388	177,063	247,839	318,140	341,379	309,510
Operating income (loss)	(60,916)	(111,443)	(146,817)	(177,448)	(209,296)	(166,896)
Interest income	2,253	1,057	3,950	—	—	—
Other income (expense)	2,253	1,057	3,950	19,693	17,902	16,396
Income tax expense (benefit)	345	411	63	2,199	1,412	939
Net income (loss)	(24,463)	(100,393)	(149,186)	40,720	(187,123)	(103,265)
Earnings per share, basic USD per share	(0.41)	(1.42)	(2.10)	0.57	(2.57)	(1.41)
Earnings per share, diluted USD per share	(0.41)	(1.42)	(2.10)	0.54	(2.57)	(1.41)
Weighted average shares, basic thousands of shares	60,025	70,595	71,173	71,776	72,670	73,443
Weighted average shares, diluted thousands of shares	60,025	70,595	71,173	74,987	72,670	73,443

Fiscal years (SDGR's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	202,296	120,267	90,474	155,315	147,326	230,517
Marketable securities	440,395	456,212	360,613	307,688	204,798	164,947
Accounts receivable	31,423	31,744	55,953	65,992	235,692	83,041
Total current assets	682,978	625,060	533,989	567,796	634,993	519,265
Property and equipment, net	5,140	10,025	14,244	—	—	—
Right-of-use asset	10,129	75,384	105,982	117,778	111,883	102,736
Goodwill	—	0	4,791	4,791	4,791	4,791
Total assets	746,263	756,487	688,587	802,955	823,226	726,160
Accounts payable	8,398	8,079	9,470	16,815	10,666	11,452
Total current liabilities	73,205	91,211	108,799	133,673	191,747	189,136
Lease liability, non-current	7,221	77,827	105,485	111,014	101,074	92,816
Total liabilities	122,244	199,402	240,682	254,397	401,781	362,107
Accumulated deficit	(129,559)	(229,952)	(379,138)	(338,418)	(525,541)	(628,806)
Total stockholders' equity	624,015	557,071	447,894	548,558	421,445	364,053
Total liabilities and equity	746,263	756,487	688,587	802,955	823,226	726,160
Common shares outstanding (cover page) thousands of shares	60,714	61,835	62,164	62,977	—	—

Fiscal years (SDGR's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(24,463)	(100,393)	(149,186)	40,720	(187,123)	(103,265)
Stock-based compensation	10,545	26,490	39,630	47,841	49,903	42,997
Depreciation and amortization	3,658	2,847	4,344	5,552	6,159	6,022
Net cash from operating activities	16,757	(70,669)	(119,683)	(136,733)	(157,368)	13,899
Purchases of property and equipment	2,538	7,167	8,014	13,403	7,311	1,442
Net cash from investing activities	(381,721)	(16,812)	90,023	193,034	148,836	57,898
Proceeds from issuing common stock	—	—	0	0	8,868	0
Net cash from financing activities	541,274	7,952	2,110	9,048	10,123	2,931
Net change in cash	176,310	(79,529)	(27,550)	65,349	1,591	74,728

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Schrodinger	287,853	58,889	(34,070)*	not reported	12.1 quarters	Q2 FY26 10-QJun 30, 2026
Mannkind	52,929	109,374	(18,371)*	321.5M	6.0 quarters	Q2 FY26 10-QJun 30, 2026
Spyre Therapeutics	82,727	not reported	(77,495)*	95.0M	15.7 quarters	Q3 FY26 10-QSep 30, 2026
Novavax	191,458	56,698	(72,807)*	164.9M	9.9 quarters	Q2 FY26 10-QJun 30, 2026
Harrow	83,889	70,661	(9,755)*	37.5M	8.6 quarters	Q2 FY26 10-QJun 30, 2026
Innoviva	570,388	119,591	51,972*	72.2M	—	Q2 FY26 10-QJun 30, 2026
Aurinia Pharmaceuticals	45,792	83,699	46,367*	134.0M	—	Q3 FY26 10-QSep 30, 2026
Ani Pharmaceuticals	360,212	266,044	56,669*	not reported	—	Q2 FY26 10-QJun 30, 2026
Celldex Therapeutics	47,454	22	(57,410)*	78.5M	12.5 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.